Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $6.11 and last traded at $7.80, with a volume of 347628 shares. The stock had previously closed at $7.24.
Analyst Ratings Changes
Separately, Noble Financial began coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating for the company.
Read Our Latest Stock Analysis on Gyre Therapeutics
Gyre Therapeutics Trading Up 4.1 %
The company has a market cap of $752.64 million, a price-to-earnings ratio of 160.80 and a beta of 2.03. The stock's fifty day simple moving average is $10.10 and its 200 day simple moving average is $11.51.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to analysts' expectations of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.
Institutional Investors Weigh In On Gyre Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its position in Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after acquiring an additional 913 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock valued at $1,386,000 after acquiring an additional 918 shares during the last quarter. Barclays PLC increased its stake in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock valued at $168,000 after acquiring an additional 1,389 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Gyre Therapeutics by 15,083.3% in the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock worth $140,000 after buying an additional 1,810 shares during the period. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Recommended Stories
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
